KIT-13
Rett Syndrome
Pre-clinicalActive
Key Facts
About NeuroCores
NeuroCores is a private, pre-clinical biotech company pioneering a novel approach to treating severe neurological conditions by targeting plasmalogen deficiency. The company's lead compound, KIT-13, is an oral small molecule for Rett syndrome that has demonstrated safety and efficacy in mouse models and has secured both FDA Orphan Drug and Rare Pediatric Disease designations. Founded in 2016 as a spin-out from Japanese research, NeuroCores is led by a team with deep neuroscience and biotech commercialization experience. The company operates at the intersection of high unmet medical need and a potentially transformative platform technology, positioning it for significant value creation if clinical translation is successful.
View full company profileTherapeutic Areas
Other Rett Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| NTI164 | Neurotech International | Phase 2 |
| RTT1 | Grann Pharmaceuticals | Pre-clinical |
| NEX-1 / NEX-2 | Nexien BioPharma | Pre-clinical / Phase 1 |
| DPM-1003 | DepYmed | Phase 1 |
| ExoEdit® for Rett Syndrome | Evox Therapeutics | Pre-clinical |
| RVL-001 (vorinostat) | Unravel Biosciences | Clinical Trial Initiated |
| Rett Syndrome Program | Herophilus | Discovery |
| Glutamate Modulator for Rett Syndrome | Numedicus | Licensed/Orphan Designation |
| TTI-0102 | Thiogenesis Therapeutics | Phase 1 |
| DAYBUE® (trofinetide) | Neuren Pharmaceuticals | Approved |
| TSHA-102 | Taysha Gene Therapies | Phase 1/2 |
| Sarizotan | Newron Pharmaceuticals | Phase III |